BUZZ-Caribou shares plunge as company explores sale and cancels cancer project
路透社2026/10/07 09:39October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)
October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72
** Caribou Biosciences said on Tuesday evening that it is exploring strategic options, including a potential sale, merger, or other transactions to maximize shareholder value
** Caribou said it plans to discontinue development of its allogeneic CAR-T cell therapy programs, including vispa-cel for the treatment of non-Hodgkin lymphoma and CB-011 for the treatment of multiple myeloma
** Caribou said it will conduct layoffs and cut costs, and expects most of the layoffs to be completed by the fourth quarter of 2026
** As of June 30, the company held $113.8 million in cash, cash equivalents, and marketable securities
** As of the close of the previous trading session, the company’s shares had fallen about 28% year-to-date
(To better serve non-English native speakers, Reuters provides automated translations of its reports into several other languages. Because machine translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of these automated translations, which are provided for the convenience of readers only. Reuters assumes no responsibility for any damage or loss resulting from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pendle Bridge integrates with BungeeExchange, supporting cross-chain transfers across 13 networks
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Crypto prices
More
